This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Organovo Cautions Investors In Regards To "Short And Distort" Articles

Stocks in this article: ONVO

SAN DIEGO, Aug. 14, 2013 /PRNewswire/ --  Organovo Holdings, Inc. (NYSE MKT: ONVO), a biotechnology company focused on delivering breakthrough three-dimensional (3D) bioprinting technology, today issued a caution to investors regarding content on certain internet sites targeting existing and potential investors in its common stock.

Organovo and many other innovative technology companies have been the subject of various articles on certain investor websites that contain significant factual errors. The content on these sites can be submitted by independent authors and do not represent a cohesive view or the opinion of the site overall. In fact, these sites do little or no fact checking, provide little to no editorial oversight, and provide limited or no mechanisms for correction of factual errors. The company would like to help investors judge content on such sites appropriately, and point out the risks of encountering false information. 

The Company would like to stress that in providing information in regards to such sites to investors, it is not claiming that all articles with a negative connotation are false. The Company respects the right of all investors and commentators to voice opinions openly. However, on some occasions information that is not factual is presented, or factual information is presented in such a way as to create a misconception. While some errors may be unintentional or simply sloppy, on some occasions it is possible that some authors may be following a "Short and Distort" strategy, where they purposefully create a negative picture after taking a short position. To be sure, not every positive article regarding the Company should be trusted either, but rather investors should bring a critical eye to all articles published on such sites, which despite having significant distribution power and readership can be lacking in content quality. 

For several reasons, Organovo strongly encourages all investors to regularly review and focus on its filings with the Securities and Exchange Commission and its press releases for information regarding the Company, including the risk language in such filings, because the first line of defense against sophistry lies with the investor. When the Company has elected to request corrections through a site publishing false information, the process can take two days to two weeks, and no site that sends out an email alert when an article is published has ever agreed to send the corrections out via email alert, meaning that admitted factual errors that required correction may never be seen by the great majority of readers of the earlier incorrect article. A number of requested corrections have never been made, because the standard for some sites to adjudicate a dispute is only to ask the author if they are willing to make a change. Above all, the Company feels that it is in the best interests of shareholders for its management team to remain primarily focused on advancing the commercialization of its bioprinting technology, rather than debating with internet bloggers. For these reasons, Organovo seeks to provide resources to keep its investor base informed and engaged, so that individual investors are best prepared to judge content for themselves.   

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,380.41 +263.17 1.63%
S&P 500 1,886.76 +24.00 1.29%
NASDAQ 4,258.4380 +41.0480 0.97%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs